Abstract:Precision medicine relies on the idea that, for a particular targeted agent, only a subpopulation of patients is sensitive to it and thus may benefit from it therapeutically. In practice, it is often assumed based on preclinical data that a treatment-sensitive subpopulation is known, and moreover that the agent is substantively efficacious in that subpopulation. Due to important differences between preclinical settings and human biology, however, data from patients treated with a new targeted agent often show that one or both of these assumptions are false. This paper provides a Bayesian randomized group sequential enrichment design that compares an experimental treatment to a control based on survival time and uses early response as an ancillary outcome to assist with adaptive variable selection and enrichment. Initially, the design enrolls patients under broad eligibility criteria. At each interim decision, submodels for regression of response and survival time on a baseline covariate vector and treatment are fit; variable selection is used to identify a covariate subvector that characterizes treatment-sensitive patients and determines a personalized benefit index, and comparative superiority and futility decisions are made. Enrollment of each cohort is restricted to the most recent adaptively identified treatment-sensitive patients. Group sequential decision cutoffs are calibrated to control overall type I error and account for the adaptive enrollment restriction. The design provides a basis for precision medicine by identifying a treatment-sensitive subpopulation, if it exists, and determining whether the experimental treatment is superior to the control in that subpopulation. A simulation study shows that the proposed design reliably identifies a sensitive subpopulation, yields much higher generalized power compared to several existing enrichment designs and a conventional all-comers group sequential design, and is robust.

A nonparametric method for value function guided subgroup identification via gradient tree boosting for censored survival data

Subgroup identification in clinical trials: an overview of available methods and their implementations with R

Subgroup detection and sample size calculation with proportional hazards regression for survival data

Bayesian Group Sequential Enrichment Designs Based on Adaptive Regression of Response and Survival Time on Baseline Biomarkers.

Statistical Performance Guarantee for Subgroup Identification with Generic Machine Learning

BLAST: Bayesian Latent Subgroup Design for Basket Trials Accounting for Patient Heterogeneity

Estimating Interpretable Heterogeneous Treatment Effect with Causal Subgroup Discovery in Survival Outcomes

Identification and inference for subgroups with differential treatment efficacy from randomized controlled trials with survival outcomes through multiple testing

Subgroup Identification using Covariate Adjusted Interaction Trees

Predictive analytics with gradient boosting in clinical medicine

A Robust Threshold T Linear Mixed Model for Subgroup Identification Using Multivariate T Distributions

An empirical comparison between gradient boosting methods and cox's proportional hazards model for right-censored survival data

PSICA: Decision trees for probabilistic subgroup identification with categorical treatments

Augmented Learning of Heterogeneous Treatment Effects via Gradient Boosting Trees

Recovering Sparse and Interpretable Subgroups with Heterogeneous Treatment Effects with Censored Time-to-Event Outcomes

Matching methods for obtaining survival functions to estimate the effect of a time-dependent treatment

Gradient Boosting Survival Tree with Applications in Credit Scoring

Teasing out the overall survival benefit with adjustment for treatment switching to other therapies

Evaluating the impact of treating the optimal subgroup

A Partitioning Deletion/Substitution/Addition Algorithm for Creating Survival Risk Groups

Optimizing Survival Analysis of XGBoost for Ties to Predict Disease Progression of Breast Cancer